For the Inventor, By the Inventor

Enter assignee name

London, United Kingdom

Cyclacel Limited

USPTO Granted Patents = 56

% Expired Patents = 51.8

CIPO Patents = 4

EPO Patents = 21

Trademarks = 3

Forward Citations = 525

Loading Chart...

Loading Chart...

83 inventors (with patents filed for the assignee):

Peter Martin Fischer (18 out of 20 patents)

Shudong Wang (11 out of 13 patents)

John Colyer (9 out of 12 patents)

4. Simon Richard Green (8 out of 15 patents)

5. Roger Kingdon Craig (7 out of 26 patents)

6. Gavin Wood (6 out of 7 patents)

7. Judy H Chiao (5 out of 11 patents)

8. Robert Westwood (4 out of 17 patents)

9. Stuart Donald Jones (4 out of 4 patents)

10. Ian Fleming (4 out of 4 patents)

11. Stuart Wilson (4 out of 4 patents)

12. Paul Workman (4 out of 8 patents)

13. Daniella I Zheleva (4 out of 4 patents)

14. Christopher Meades (4 out of 5 patents)

15. Edward McDonald (4 out of 22 patents)

Core Competencies:

Purine Derivatives

Pyrimidine Compounds

CDK Inhibitors

Acute Myeloid Leukemia

Sapacitabine

Combination Therapy

Protein Kinase Inhibitors

Anticancer Agents

Dosing Regimens

Crystalline Forms

Transport Vectors

Anti-Proliferative Compounds

56 patents: Sort by Forward Citations

1. 10927113 - Process for preparing purine derivatives (2021-02-23),

2. 10226478 - Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia (2019-03-12),

3. 9872874 - Dosage regimen for sapacitabine and seliciclib (2018-01-23),

4. 9675631 - Dosing regimens for treatment of proliferative disorders comprising administration of sapacitabine (2017-06-13),

5. 9573951 - Crystalline forms of a purine derivative (2017-02-21),

6. 9493471 - Pyrimidine derivatives as protein kinase inhibitors (2016-11-15),

7. 9173938 - Combination of a purine-based CDK inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders (2015-11-03),

8. 9133199 - Pyrimidine derivatives as protein kinase inhibitors (2015-09-15),

9. 8975239 - Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine (2015-03-10),

10. 8889861 - Crystalline forms of a purine derivative (2014-11-18),

11. 8884001 - Preparation of intermediates useful in the synthesis of 2'-cyano-2′-deoxy-N4-palmi-toyl-1-β-D-arabinofuranosylcytosine (2014-11-11),

12. 8846696 - Purine derivatives (2014-09-30),

13. 8809350 - Purine and pyrimidine CDK inhibitors and their use for the treatment of autoimmune diseases (2014-08-19),

14. 8592581 - Trisubstituted purine derivatives (2013-11-26),

15. 8563542 - Pyrimidine derivatives as protein kinase inhibitors (2013-10-22),

Company Overview

Cyclacel Limited is a biotechnology company based in London, specializing in the development of innovative cancer treatment compounds. The company focuses on advancing therapies that target critical pathways in cancer cells, particularly through the use of purine and pyrimidine derivatives, as well as CDK inhibitors. Cyclacel's research is centered on addressing acute myeloid leukemia and enhancing treatment efficacy through combination therapies, positioning it as a key player in the oncology sector.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

56 Patents

#75 in London

#317 in United Kingdom

#12,761 in the World

London, United Kingdom

Cyclacel Limited

Forward Citations = 525

83 inventors:

Peter Martin Fischer (18 out of 20 patents)

Shudong Wang (11 out of 13 patents)

John Colyer (9 out of 12 patents)

4. Simon Richard Green (8 out of 15 patents)

5. Roger Kingdon Craig (7 out of 26 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cyclacel Limited. Retrieved from https://idiyas.com/company/cyclacel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…